# EDGAR Filing Document

**Accession Number:** 0001787306
**File Stem:** 0000000000-25-009956
**Filing Date:** 2025-9
**Character Count:** 5994
**Document Hash:** 0687e61bb057c441a84d99bc14df2516
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009956.hdr.sgml**: 20260701

**ACCESSION NUMBER**: 0000000000-25-009956

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250915

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcutis Biotherapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001787306
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812974255
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-39186

**BUSINESS ADDRESS:**
- **STREET 1:** 3027 TOWNSGATE ROAD
- **STREET 2:** SUITE 300
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361
- **BUSINESS PHONE:** 805-418-5006

**MAIL ADDRESS:**
- **STREET 1:** 3027 TOWNSGATE ROAD
- **STREET 2:** SUITE 300
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arcutis, Inc.
- **DATE OF NAME CHANGE:** 20190905
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001787306-25-000029

## Text-Extract

```

                                                            September 15, 2025

Latha Vairavan
Chief Financial Officer
Arcutis Biotherapeutics, Inc.
3027 Townsgate Road Suite 300
Westlake Village, California 91361

       Re: Arcutis Biotherapeutics, Inc.
           Form 10-K for the Fiscal Year Ended December 31, 2024
           Filed February 25, 2025
           File No. 001-39186
Dear Latha Vairavan:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for the Fiscal Year Ended December 31, 2024
Item 7. Management's Discussion and Analysis of Financial Condition and Results
of
Operations
Results of Operations - Product Revenue, Net, page 103

1.     We note your disclosure on page 103 that the $55.9 million, or over
100%, increase to
       ZORYVE cream 0.3% net product revenue at December 31, 2024 was primarily
due
       to higher end customer demand and improving gross-to-net discounts for
ZORYVE
       cream 0.3%. We also note your disclosures in the financial statements
that
       you recorded accrued sales deductions of $38.4 million & $11.6 million
at December
       31, 2024 and December 31, 2023. Given the significant increase in
product revenues
       and the existence of chargebacks, rebates, returns, prompt pay
discounts, and other
       deductions, please provide the following with a view toward future
disclosure:
           Given your product sales in Canada since 2023, quantify for us how
much of
           product sales are non-U.S for all periods and if you expect the
future trend to
           change.
 September 15, 2025
Page 2

             Provide us a roll forward of the accrual for each estimate for the
year ended
           December 31, 2024 showing the following:
            o Beginning balance,
            o Current provision related to sales made in current period,
            o Current provision related to sales made in prior periods,
            o Actual returns or credits in current period related to sales made
in current
               period,
            o Actual returns or credits in current period related to sales made
in prior
               periods, and
            o Ending balance.

             Separately tell us:
            o The effect that could result from using other reasonably likely
assumptions
               than what you used to arrive at each accrual such as a range of
reasonably
               likely amounts or other type of sensitivity analysis.
            o Please provide us a discussion of the amount of and reason for
fluctuations
               for each type of reduction of gross revenue (i.e. product
returns, chargebacks,
               customer rebates and other discounts and allowances) including
the effect
               that changes in your estimates of these items had on your
revenues and
               operations.
Note 8. Commitments and Contingencies, page F-24

2.     We note your disclosure in Item 3 on page 96 of the patent infringement
complaints
       filed against you by Teva Pharmaceutical Industries Ltd. on August 13,
2024 and
       September 20, 2024 with the European Patent Office. We also note that
you did not
       include disclosure of your estimate of potential exposure to loss
contingencies in Note
       8, Commitments and Contingencies, on page F-24. Please tell us how you
applied
       ASC 450-20-25 in assessing the likelihood of the loss or impairment of
an asset or the
       incurrence of a liability as a result of the litigation, and your
consideration of
       providing the disclosures required by ASC 450-20-50-3 through 50-5 as it
relates to
       this potential loss contingency, including the amount or range of
reasonably possible
       losses in excess of recorded amounts.
        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.

       Please contact Bonnie Baynes at 202-551-4924 or Angela Connell at
202-551-3426
with any questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._